Related Experiment Video
Updated: Feb 13, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function
Hua V Lin1, Jingru Wang2, Jie Wang2
1Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA.
Objective:
GPR142 agonists are being pursued as novel diabetes therapies by virtue of their insulin secretagogue effects. But it is undetermined whether GPR142's functions in pancreatic islets are limited to regulating insulin secretion. The current study expands research on its action.
Methods And Results:
We demonstrated by in situ hybridization and immunostaining that GPR142 is expressed not only in β cells but also in a subset of α cells. Stimulation of GPR142 by a selective agonist increased glucagon secretion in both human and mouse islets. More importantly, the GPR142 agonist also potentiated glucagon-like peptide-1 (GLP-1) production and its release from islets through a mechanism that involves upregulation of prohormone convertase 1/3 expression. Strikingly, stimulation of insulin secretion and increase in insulin content via GPR142 engagement requires intact GLP-1 receptor signaling. Furthermore, GPR142 agonist increased β cell proliferation and protected both mouse and human islets against stress-induced apoptosis.
Conclusions:
Collectively, we provide here evidence that local GLP-1 release from α cells defines GPR142's beneficial effects on improving β cell function and mass, and we propose that GPR142 agonism may have translatable and durable efficacy for the treatment of type 2 diabetes.
Insights
GPR142 agonists enhance insulin secretion and beta cell function. This study reveals GPR142
Area of Science:
- Endocrinology
- Molecular Biology
- Diabetes Research
Background:
- G protein-coupled receptor 142 (GPR142) agonists are investigated for type 2 diabetes due to insulin-stimulating properties.
- The precise roles of GPR142 within pancreatic islets beyond insulin secretion remain largely unexplored.
Purpose of the Study:
- To investigate the broader functions of GPR142 in pancreatic islet cells.
- To elucidate the mechanisms underlying GPR142's effects on islet cell function and survival.
Main Methods:
- In situ hybridization and immunostaining to determine GPR142 expression patterns in pancreatic islets.
- Treatment of human and mouse islets with a selective GPR142 agonist.
- Assessment of glucagon and insulin secretion, prohormone convertase 1/3 (PC1/3) expression, and beta cell proliferation and apoptosis.
Main Results:
- GPR142 is expressed in both alpha (α) and beta (β) cells.
- GPR142 stimulation increases glucagon secretion and enhances glucagon-like peptide-1 (GLP-1) production and release via PC1/3 upregulation.
- GPR142-mediated insulin secretion and content increase depend on intact GLP-1 receptor signaling; GPR142 also promotes β cell proliferation and protects islets from apoptosis.
Conclusions:
- Local GLP-1 release from α cells is a key mediator of GPR142's beneficial effects on β cell function and mass.
- GPR142 agonism demonstrates potential for treating type 2 diabetes through improved β cell function and survival.
- GPR142 activation offers a promising therapeutic strategy for type 2 diabetes management.
Related Concept Videos
Hypoglycemia and Glucagon
Antihypertensive Drugs: Action of β1 Blockers
Peptide Bonds
Cell Specific Gene Expression
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Improving Translational Accuracy

